Abbott Laboratories (ABT): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Abbott Laboratories ( ABT) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.4%. By the end of trading, Abbott Laboratories fell 71 cents (-1.1%) to $64.29 on average volume. Throughout the day, 6.6 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.5 million shares. The stock ranged in price between $64.18-$65.32 after having opened the day at $65.09 as compared to the previous trading day's close of $65. Other companies within the Drugs industry that declined today were: Oxygen Biotherapeutics ( OXBT), down 13.6%, Biocryst Pharmaceuticals ( BCRX), down 12.2%, Delcath Systems ( DCTH), down 9.3%, and Sucampo Pharmaceuticals Inc. A ( SCMP), down 8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $102.87 billion and is part of the health care sector. The company has a P/E ratio of 15.9, below the S&P 500 P/E ratio of 17.7. Shares are up 15.6% year to date as of the close of trading on Friday. Currently there are six analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Neuralstem ( CUR), up 19.2%, Cyclacel Pharmaceuticals ( CYCC), up 18.3%, Idera Pharmaceuticals ( IDRA), up 13.5%, and MEI Pharma ( MEIP), up 12.3%, were all gainers within the drugs industry with Novo Nordisk A/S ( NVO) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

The Best Companies for Women

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Alibaba, Qorvo, Abbott Laboratories, Square: 'Mad Money' Lightning Round

Walmart Is One of 63 Companies Contributing Massively to Aid Harvey Relief